Ectopic expression of Oct4, Sox2, cMyc, and Klf4 confers a pluripotent state upon several differentiated cell types, generating induced pluripotent stem cells (iPSCs) [1] [2] [3] [4] [5] [6] [7] [8] . iPSC derivation is highly inefficient, and the underlying mechanisms are largely unknown. This low efficiency suggests the existence of additional cooperative factors whose identification is critical for understanding reprogramming. In addition, the therapeutic use of iPSCs relies on the development of efficient nongenetic means of factor delivery, and although a handful of replacement molecules have been identified, their use yields a further reduction to the already low reprogramming efficiency [9] [10] [11] . Thus, the identification of compounds that enhance rather than solely replace the function of the reprogramming factors will be of great use. Here, we demonstrate that inhibition of Tgfbb signaling cooperates in the reprogramming of murine fibroblasts by enabling faster, more efficient induction of iPSCs, whereas activation of Tgfb signaling blocks reprogramming. In addition to exhibiting a strong cooperative effect, the Tgfb receptor inhibitor bypasses the requirement for exogenous cMyc or Sox2, highlighting its dual role as a cooperative and replacement factor. The identification of a highly characterized pathway operating in iPSC induction will open new avenues for mechanistic dissection of the reprogramming process.
We identified Tgfb signaling as a potential cooperative pathway in reprogramming during functional validation of a constructed network that linked retroviral insertion sites across several mouse iPSC lines [12] . Although the biological validation of network targets was largely negative, in agreement with statistical analyses suggesting that the network did not differ from randomly constructed networks, we found that use of a Tgfb receptor I kinase/activin-like kinase 5 (Alk5) inhibitor could enhance the efficiency of iPSC derivation.
To induce reprogramming, we infected mouse embryonic fibroblasts (MEFs) carrying a reverse tetracycline transactivator (rtTA) transgene with doxycycline (dox)-inducible lentiviruses encoding the four reprogramming factors as previously described [13] . Administration of the Alk5 inhibitor during the course of dox induction elicited a striking increase in the number of iPSC colonies ( Figure 1A ). These iPSC clones could be expanded in the absence of dox, which is a strong indicator of successful reprogramming [13, 14] .
This robust increase in efficiency led us to examine whether the Alk5 inhibitor could also reduce the temporal requirement of factor expression and thus reflect an increase in the kinetics of reprogramming. To test this, we applied dox for three, four, or five days on four-factor infected MEFs, in either the presence or the absence of the Alk5 inhibitor ( Figure 1B ). Although we were unable to obtain iPSCs with 3 days of dox treatment in either condition, 4 days of dox treatment was sufficient to give rise to iPSC colonies at a frequency of 0.0013% in the inhibitor-treated condition. These colonies were not immediately apparent and took at least 1 week after dox withdrawal to emerge. No colonies were observed in the control condition, demonstrating that the inhibitor promoted faster induction of iPSCs. Four-day iPSCs expressed the pluripotency markers Nanog, Oct4, and Sox2 ( Figure 1C ), and we tested for these markers three passages after dox withdrawal to ensure a lack of residual transgene expression [14] . These cells were also competent to form lineages from all three germ layers in the context of a teratoma ( Figure 1C) , providing a functional test of pluripotency and indicating that use of the Alk5 inhibitor during reprogramming has no adverse effect on the resulting iPSCs.
We next sought to establish a dose-response curve for the Alk5 inhibitor. Using four-factor-infected MEFs, we tested concentrations of the Alk5 inhibitor over a 1000-fold range, from 4 nM to 4 mM. Increasing concentrations of inhibitor led to a progressive increase in the number of iPSC colonies obtained and resulted in a 30-fold enhancement at the highest dose tested ( Figure 1D ).
To verify that manipulation of Tgfb signaling affects reprogramming, we investigated whether pathway activation would inhibit iPSC formation. Using four-factor-infected MEFs, we applied increasing concentrations of Tgfb1 or Tgfb2 during the time of dox induction. Under control conditions, we obtained an average of 14 colonies per well (w0.017%); however, upon addition of 1 ng/ml Tgfb1 or Tgfb2, the efficiency was reduced to one colony per well (w0.0013%), and at 2.5 ng/ml and 5 ng/ml, iPSC formation was undetectable ( Figure 1E ). The opposing effects of pathway activation and inhibition confirm the involvement of Tgfb signaling in reprogramming.
To gain further insight into the mode of action of the Alk5 inhibitor, we next examined the temporal window during which the inhibitor elicited its strongest effect. In four-factor-infected MEFs, the inhibitor was applied in 4 day intervals from days 0-16 of reprogramming. The largest increase in efficiency was observed during the first 4 days of reprogramming and yielded an increase comparable to that obtained by full-time application of the inhibitor ( Figure 1F ). A strong enhancement was also observed with application during the 5-8 day interval, whereas after dox withdrawal (day 12), the inhibitor appeared to have no effect.
This early-acting effect prompted us to investigate whether the Alk5 inhibitor was acting to ''prime'' the cells and thus to alter or destabilize the fibroblast state so that it is more amenable to reprogramming. To test this, we applied the inhibitor in 3 day time intervals: before dox administration (days 23 to 0) to test for a priming effect; during the first 3 days of reprogramming (days 0 to +3) as a control for the efficiency increase; and during both intervals (days 23 to +3) to test for a synergistic effect. We also included a no-inhibitor control as a baseline measure ( Figure 1G ). Administration of the Alk5 inhibitor prior to expression of the reprogramming factors (days 23 to 0) led to a slight reduction in efficiency, thus arguing against a priming effect. In contrast, addition of the inhibitor during the first 3 days of factor expression led to an approximately 5-fold enhancement in efficiency, consistent with our previous findings. The increase in efficiency seen in the group that received inhibitor during days 23 to +3 was comparable to that seen in the group that received inhibitor during days 0 to +3, indicating a lack of a synergistic effect. It therefore appears that Alk5 inhibition must coincide with expression of the reprogramming factors in order to elicit its effect.
One limitation of direct infection is that not every cell receives the full complement of reprogramming factors, and there is a large amount of heterogeneity in expression because each cell harbors a unique pattern of viral insertions. It is therefore difficult to ascertain whether the increase in efficiency we have observed so far is due solely to a cooperative effect, where the inhibitor enhances efficiency in the presence of all four factors, or to a replacement effect, where the inhibitor substitutes for specific reprogramming factors. To this end, we employed a ''secondary system'' consisting of MEFs isolated from iPSC-derived chimeras. These MEFs contain a homogenous set of inducible lentiviral integrations that are permissive for conversion into primary iPSCs; thus, the levels and stoichiometry of the re-expressed factors are unique to each MEF line [14, 15] .
In two different secondary MEF lines, we tested the effect of Alk5 inhibition on both the efficiency and kinetics of reprogramming. In this experiment, we applied dox for 4, 6, 8, or 10 days, either in the presence or absence of the Alk5 inhibitor, then quantified iPSC colony number on day 16. The baseline levels of reprogramming differed between the two lines (Figure 2A ), which was not unexpected given that efficiency is dependent upon the levels and stoichiometry of factor expression, as previously reported [15] . In both lines, addition Tgfb concentrations were defined as follows: low, 1 ng/ml; medium, 2.5 ng/ml; and high, 5ng/ml. (F) Timing of Alk5 inhibitor action. The Alk5 inhibitor (1 mM) was applied in 4 day time intervals. Control = no inhibitor, full-time = inhibitor added on days 1-16. Dox was withdrawn on day 12, and colonies were quantified on day 16 on the basis of Oct4 immunostaining. Error bars represent standard deviation.
(G) Priming effect of the Alk5 inhibitor. Inhibitor (1 mM) was applied for 3 days before (days 23 to 0) dox induction, during the first 3 days of dox induction (days 0 to +3), or both (days 23 to +3). Control = no inhibitor. Dox was withdrawn on day 8, and colonies were quantified on day 12 on the basis of Oct4 immunostaining. Error bars represent standard deviation.
of the Alk5 inhibitor mediated an increase in both efficiency and kinetics of reprogramming, consistent with a cooperative effect ( Figure 2A) . However, the degree to which reprogramming was enhanced was different between the two lines, one of which showed a 2-fold increase and the other a 30-fold increase. We reasoned that a purely cooperative action would produce a consistent increase between the different lines regardless of variation in factor expression levels, and this was not the case. Thus, to further discern between a cooperative and a replacement effect, we employed a polycistronic construct linking all four reprogramming factors on a single transcript (''STEMCCA'') [16] , which in the context of a secondary system enables expression of all factors in >95% of cells (data not shown). In such a system, only a cooperative effect would be revealed because coexpression of all factors precludes factor replacement. We used these secondary STEMCCA MEFs to establish another dose-response curve for the Alk5 inhibitor. In contrast to primary infected MEFs, which demonstrated a steady increase across the entire dose range tested ( Figure 1D ), the STEMCCA MEFs reached a maximum efficiency at 0.5 mM, representing an approximately 60-fold increase, and efficiency declined at higher doses ( Figure 2B) . A similar pattern was also observed with another inhibitor, SB-431542, that targets the type I Tgfb receptors, Alk-4, -5, and -7 ( Figure S1 ). These data corroborate the notion of a cooperative effect and also introduce the possibility of a factor-replacement effect that operates at a different dose range, thus explaining the persistent efficiency increase with higher doses of the Alk5 inhibitor in primary infected MEFs ( Figure 1D ) and the decline in the secondary STEMCCA MEFs.
We therefore set out to investigate whether the Alk5 inhibitor could function to replace exogenous expression of any of the reprogramming factors. To this end, we infected primary MEFs with different combinations of the four factors in the presence or absence of inhibitor (Table S1 ) and then scored for iPSC formation. In the four-factor control infection (OSMK; O = Oct4, S = Sox2, M = cMyc, and K = Klf4), colonies were already apparent after 6 days; we therefore withdrew dox on day 8 to avoid detrimental effects of prolonged factor expression [17] . At this time we also observed colonies in the cMyc replacement condition (OSK + inhibitor), but none in the condition without the inhibitor; thus, we withdrew dox from these cultures on day 8 as well. Remarkably, use of the Alk5 inhibitor (OSK + inhibitor) in place of cMyc resulted in a 2.5-fold higher efficiency than with the four factors alone (OSK + M), indicating that Alk5 inhibition was more potent than the action of cMyc in promoting reprogramming ( Figure 2C) . For all of the other replacement conditions, we withdrew dox on day 16, which we reasoned would provide sufficient time for reprogramming. Although most conditions did not yield any obvious colonies, the Sox2 replacement condition contained numerous colonies morphologically similar to iPSCs. Appearing late in reprogramming, these colonies became readily visible after 14 days. On the basis of morphology, we counted 50 colonies in the inhibitor-treated culture and four colonies in the control condition as being identical to iPSCs (data not shown). Withdrawal of dox, however, led to regression of many colonies in both conditions, indicating that the cells were not independent of factor expression. Nonetheless, we picked colonies from both conditions and tested their potential to form dox-independent lines. From the control condition, 0/4 were capable of expansion, indicating that infection with the three factors (OMK) was not sufficient to induce reprogramming, whereas in the inhibitor-treated culture, 3/22 picked colonies formed dox-independent iPSC lines, demonstrating successful replacement of Sox2. The efficiency of expansion was low compared to that of four-factor iPSC clones, where all picked colonies (6/6 in this set of experiments) were capable of forming stable dox-independent lines.
Immunostaining of the OMK + inhibitor iPSC lines demonstrated expression of Nanog, Oct4, and Sox2 (tested after three passages without dox) ( Figure 2E ). To further verify expression of pluripotency genes, we performed quantitative RT-PCR analysis by using primer sets that distinguish endogenous and viral transcripts ( Figure S2A ), which revealed pluripotency gene activation and viral gene silencing. To functionally assess pluripotency of the OMK + inhibitor iPSCs, we generated teratomas, which contained lineages from all three germ layers ( Figure S2B ). We also tested the ability of these cells to contribute to chimeric mice; to this end, we labeled iPSCs with a lentivirus constitutively expressing the red fluorescent protein, tdTomato, sorted the cells by flow cytometry, and injected them into blastocysts. Mice harvested on embryonic day E16.5 showed varying degrees of contribution ( Figure 2F ). As a more stringent test of pluripotency, we were also able to generate adult chimeras ( Figure 2G ), though their potential for germline transmission has not yet been evaluated. To ensure that these iPSCs were free of Sox2 viral integrations, we performed Southern blot analysis by using a Sox2 cDNA probe. No extraneous bands were observed in the OMK + inhibitor lines, confirming the absence of exogenous Sox2 ( Figure S2C) .
As a final test to determine whether the Alk5 inhibitor enabled iPSC formation under any of the replacement conditions, we passaged the primary cultures in the absence of dox, which would permit the amplification and selection of rare dox-independent cells that may not have been visible in the initial culture. We excluded OSK and OSMK conditions because these readily formed iPSCs. Confirming our observations from the primary cultures, only the Sox2-replacement condition (OMK + inhibitor) gave rise to dox-independent colonies ( Figure 2D ). The control condition (OMK , no inhibitor) also contained colonies that expressed alkaline phosphatase (Figure 2D, upper left) ; however, these colonies appeared to be fibroblastic and did not grow, indicating that they were not iPSCs. Interestingly, although the Alk5 inhibitor enabled colony formation in the absence of either cMyc or Sox2, we could not obtain any colonies in the absence of both factors (OK; Figure 2D ), suggesting that the inhibitor performs distinct functions from Sox2 and cMyc but can preferentially assume their role in the context of reprogramming with the three remaining factors.
The results presented here demonstrate that Tgfb receptor I kinase inhibition enhances both the efficiency and kinetics of reprogramming in a dose-dependent manner, whereas activation of the Tgfb signaling pathway blocks reprogramming. The Alk5 inhibitor exerts its strongest effect during the early stages of iPSC induction and acts in concert with the reprogramming factors to mediate its effect, rather than converting the fibroblasts to a state more amenable to reprogramming. In addition to its cooperative action, the Alk5 inhibitor can replace the individual roles of cMyc or Sox2, although it cannot replace them simultaneously. These results provide the first defined pathway that both produces a strong cooperative effect and can preferentially replace the roles of specific reprogramming factors.
An important remaining question is how Alk5 inhibition acts on a molecular level to enhance reprogramming. We observed that application of the inhibitor prior to factor expression was unable to mediate an increase in efficiency, which is suggestive of a transient effect and/or one that is context dependent, in that it requires expression of the reprogramming factors to carry out its role. The observation that the Alk5 inhibitor acts early in reprogramming raises the question of whether it helps shut down the fibroblast gene-expression program. In support of this, it has been shown that activation of Tgfb signaling can promote an epithelial-to-mesenchymal transition [18] ; fibroblast reprogramming involves a mesenchymal-to-epithelial conversion, which may be enhanced by inhibition of the Tgfb signaling pathway.
An enhancement in efficiency could also be mediated through increased proliferation. We tested this possibility by examining proliferation rates during reprogramming but found that the inhibitor led to a decrease in proliferation around day 6 ( Figure S3A ). We noted that the inhibitor also mitigated the decrease in cell number that normally accompanies reprogramming (day 2) ( Figure S3A) ; however, the magnitude of this effect was unlikely to explain the large increase in overall reprogramming efficiency. Furthermore, quantification of apoptosis with Annexin V staining showed a negligible difference between inhibitor-treated and untreated cells ( Figure S3B) .
As yet another possibility, we tested the Alk5 inhibitor in the context of reprogramming by cell fusion (embryonic stem cells + MEFs), which led to a negative result (data not shown). This observation raises the question of whether Alk5 inhibition acts on direct-reprogramming pathways that are already operational in embryonic stem cells (ESCs) or whether the mechanisms of reprogramming by direct factors and cell fusion are fundamentally different.
The finding that the Alk5 inhibitor could replace either cMyc or Sox2, but not both, suggests that its functions are distinct from those of these reprogramming factors. It is possible that replacement of both factors could occur with different doses of the inhibitor or with a longer period of dox administration; however, the conditions we used that enabled replacement of the individual factors were unable to elicit simultaneous replacement, indicating a unique mode of action. We tested whether the Alk5 inhibitor simply led to induction of Sox2 or cMyc expression; however, analysis by qRT-PCR revealed that only cMyc was significantly induced (1.3-fold) in OSK + inhibitor-treated cells ( Figure S4) , and there was no significant induction of Sox2 or cMyc in any of the other cells (OMK or OSMK). A possibility is that the Alk5 inhibitor acts on a pathway that completely bypasses the need for the individual reprogramming factors; for instance, it has been shown that Sox2 is not required for reprogramming by fusion of mESCs and human B lymphocytes [19] .
Several Tgfb superfamily members represent important contributors to the pluripotent state. For instance, BMP4 signaling helps maintain mouse ESCs in an undifferentiated state [20] , and use of an Alk5 inhibitor in conjunction with GSK3b and MEK inhibitors facilitates rat and human iPSCline propagation and supports a mouse ESC-like phenotype [21] . In contrast to its pluripotency-promoting effect in mouse ESCs, BMP4 induces differentiation of human ESCs toward trophectoderm [22] , whereas Activin signaling maintains pluripotency of hESCs [23] . The differential requirements of Tgfb signaling in mouse and human ESCs may explain why we did not observe an increase in the efficiency of human fibroblast reprogramming (data not shown); it will be interesting to see whether activation of other pathways that promote the undifferentiated state also enhance reprogramming.
The highly characterized nature of the Tgfb signaling pathway makes it an attractive model for examining how interactions between downstream targets and the four factors synergize to enhance reprogramming. The identification of such pathways will greatly facilitate our understanding of reprogramming at the molecular level and potentially lead to the discovery of novel targets that promote reprogramming and are of therapeutic value.
Experimental Procedures
Virus Production Vectors were constructed as previously described [13] . Viruses were produced and titered by the University of Iowa Gene Transfer Vector Core. For all experiments, cells were infected overnight at a multiplicity of infection of 10 in the presence of 6 mg/ml polybrene, which was experimentally determined to infect >90% of cells.
Cell Culture and iPSC Induction Cells were obtained from mice harboring a reverse tetracycline transactivator (rtTA) in the Rosa locus [24] . Fibroblasts were derived from E14.5 mice; all experiments were conducted prior to passage 3. To induce reprogramming, we infected cells with the viral cocktail, then split them two days later into ESC media (15% FBS, Invitrogen; 1000 U/ml LIF) with doxycycline (1mg/ml). Fibroblast feeder cells were used only to maintain iPSC lines and not during reprogramming. The Alk5 inhibitor (Calbiochem/EMD 616452) was used at a concentration of 1 mM unless otherwise noted. The Alk-4/5/ 7 inhibitor, SB-431542, was obtained from Sigma; Tgfb ligands were obtained from Peprotech (Tgfb1, 100-21; Tgfb2, 100-35).
Alkaline Phosphatase and Immunostaining
Alkaline phosphatase (AP) staining was done with an AP substrate kit according to manufacturer directions (VectorLabs, SK-5100). The following antibodies were used for immunostaining: a-Nanog (1:200, ab21603, Abcam), a-Oct4 (1:100sc-8628, Santa Cruz Biotech), and a-Sox2 (1:200, AB5603, Millipore).
Quantitative RT-PCR RNA was extracted with a Qiagen RNeasy kit (74104), then converted to cDNA with the Superscript III First-Strand synthesis system (Invitrogen) and oligo-dT primers. qRT-PCRs were carried out with Brilliant II SYBR Green mix (Stratagene) and run on a Stratagene MXPro400. Reactions were carried out in duplicate with 2RT controls, and data were analyzed by the delta-delta Ct method.
Apoptosis Assay
Annexin V and propidium iodide staining were done with the Annexin V-FITC kit (BD Pharmingen, 556547) according to manufacturer directions. Cells were analyzed by flow cytometry on a FACSCalibur (BD).
Teratomas
A 25 cm 2 equivalent of confluent iPSCs grown on feeders was harvested and injected subcutaneously into SCID mice. Teratomas were harvested 3 weeks later and stained with hematoxylin and eosin.
Blastocyst Injections BDF1 females were superovulated with pregnant mare serum gonadotropin and hCG, then mated with BDF1 males. Blastocysts were flushed from uterine horns on day 3.5, and 10-20 labeled iPSCs were injected per blastocyst. Swiss-webster mice were set up with vasectomized males and used as recipients for the injected blastocysts.
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